RetaCalc
Protocol library
BlendNot ApprovedMixedVery Low confidenceSourced

BPC-157 / TB-500 blend

A combined research product without controlled human evidence for the mixture. Component-level preclinical claims do not establish compatibility or a blend protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

A community 1:1 BPC-157 / TB-4 blend reconstituted in one vial (10 mg = 5 mg + 5 mg), shown as total blend mass per subcutaneous injection - loading then a lower maintenance phase. Community reports only, not a validated schedule.

Evidence source
Reported maximum quantity
Loading then maintenance (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported quantities by phase

Select a point for its calculation examples
  1. Loading (3x/day)
    ~1 mg total
    Per-injection blend of ~500 mcg BPC-157 + ~500 mcg TB-4; per-component loading anecdotes span 350-650 mcg, three times daily for 5-10 days. Community claims TB-500 sold today is TB-4.
  2. Maintenance (1-2x/day)
    ~700 mcg total
    Step down for maintenance
    Per-injection blend of ~350 mcg of each component once or twice daily; frequency and duration are not standardised.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected ~1 mg total reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator
Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface
One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.
BAC water selected
2 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

1 mL BAC
10 units

resulting U-100 draw

Concentration
10 mg/mL
BAC added
1 mL
2 mL BAC
20 units

resulting U-100 draw

Concentration
5 mg/mL
BAC added
2 mL

Shown in the diagram. Closest of these examples to 25 units.

3 mL BAC
30 units

resulting U-100 draw

Concentration
3.333 mg/mL
BAC added
3 mL

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational schedule for an equal 5 mg plus 5 mg blend

600 mcg total daily in weeks 1-2, 800 mcg in weeks 3-4 and 600 mcg in weeks 5-8, delivering equal mass of each component

This is a community blend convention with no controlled human mixture study. It cannot establish component identity, compatibility or a validated outcome.

View source
Community GuideSubcutaneous in reportsOnce or twice daily; full-length TB4 reports also use twice weekly
online research community blend reports

Daily reports commonly use about 250-750 mcg of each component once or twice daily; one channel summary gives BPC-157 200-500 mcg daily plus full-length TB4 500-1,000 mcg daily or 2-4 mg twice weekly

The archive frequently interchanges TB-500 fragment and full-length thymosin beta-4, so these schedules are not molecularly equivalent. No controlled human mixture study is documented; raw/peptide-education/pe-bpc-157.md:197-216 and 1332-1340.

View source
Community GuideSubcutaneous or ophthalmic in reportsUp to 3x daily loading, reduced for maintenance
authenticated research-forum (Peppys) BPC-157 and TB-4 blend reports

An authenticated forum protocol reconstitutes BPC-157 and TB-4 together as a 1:1 blend in one vial and doses 350-650 mcg of each component subcutaneously three times daily for 5-10 days of loading, stepping down to roughly 350 mcg of each once or twice daily for maintenance; the same archive treats the peptide sold today as TB-500 as short-acting TB-4 and keeps a separate BPC-157 eye-drop protocol that is not injected

Forum provenance from an authenticated archive with usernames and post numbers omitted. The community claim that current TB-500 is TB-4 (CAS 77591-33-4) drives the daily, BPC-like schedule; reported quantities conflict and no controlled human study of the mixture exists. Subcutaneous and ophthalmic uses are kept separate rather than interconverted.

View source

Evidence summary

A combined research product without controlled human evidence for the mixture. Component-level preclinical claims do not establish compatibility or a blend protocol.

Protocol basis

The evidence is assessed component by component because no matched human trial of the blend was found. Neither component supplies a validated routine protocol.

Community provenance (Peppys)

An authenticated research-forum archive describes a 1:1 BPC-157 and TB-4 blend reconstituted in a single vial, with subcutaneous loading in the region of 350-650 mcg of each component up to three times daily for five to ten days before a lower one-to-two-times-daily maintenance phase. The archive treats the material sold today as TB-500 as short-acting TB-4, which is why it is dosed daily rather than on the older twice-weekly fragment schedule, and it keeps a separate, non-injected BPC-157 eye-drop protocol distinct from the injectable blend. Reported quantities conflict, usernames and post numbers are omitted, and the figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported quantities as a total blend mass; it does not validate them.

What remains uncertain

Combined pharmacokinetics, chemical compatibility, stability, safety and clinical outcomes are unknown.

Warnings and contraindications

No adequate controlled human study of the combined formulation was identified.
BPC-157 and TB-500 each have major evidence and product-identity gaps.
Mixing adds unresolved stability, sterility, compatibility and exposure questions.
Organised research bench with labelled storage tray, vial rack, notebook and thermometer
A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.